. Author manuscript; available in PMC: 2016 Apr 15.

Published in final edited form as: J Immunol. 2012 Oct 3;189(10):5029–5036. doi: 10.4049/jimmunol.1201892

Table 6.

Univariate Analyses of factors associated with Relapse-free Survival and Overall Survival in HER2 Positive breast cancer patients (n=64).

Variables	Relapse-free Survival			Overall Survival
Variables	HR	95% CI	P	HR	95% CI	P
CD4 (>16)	2.95	0.95 to 9.21	0.067	3.25	1.22 to 8.67	0.017
CD8 (>13)	0.09	0.01 to 0.67	0.001	0.28	0.09 to 0.87	0.016
γδ T (>9)	39.39	4.99 to 310.65	5.42E-07	35.79	4.51 to 283.87	1.28E-06
FoxP3 (>12)	6.67	1.79 to 24.70	0.001	9.10	2.60 to 31.81	4.29E-05
ER status (Pos)	4.02	0.52 to 31.17	0.106	3.24	0.73 to 14.28	0.073
Stage (III vs I + II)	13.77	4.06 to 46.67	1.85E-05	13.53	4.53 to 40.47	2.05E-06
Nodal (Pos)	NA	NA	6.85E-08	14.84	3.36 to 65.43	3.44E-06
Size (>2.1)	2.93	0.88 to 9.77	0.068	4.23	1.38 to 13.04	0.006

Note: Results obtained using the Cox proportional hazard regression model.

Abbreviations: HR, hazard ratio; ER, estrogen receptor; FoxP3, forkhead box protein P3.

NA: not analysis. All patients with negative nodal status were no recurrence and alive during the follow-up period, and the software cannot perform the analysis.